Nelivaptan

Nelivaptan

SCHEMBL4307280

COc1ccc(S(=O)(=O)N2C(=O)C(c3ccccc3OC)(N3CC(O)CC3C(=O)N(C)C)c3cc(Cl)ccc32)c(OC)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

AVPR1B

The experimentally established mechanism targets of Nelivaptan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
AVPR1B known ✓ P47901 20/20 1.00
AVPR1A P37288 11/20 1.00
OXTR P30559 11/20 1.00
AVPR2 P30518 3/20 1.00
GPR65 Q8IYL9 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Nelivaptan SCHEMBL5349223 1.00 AVPR1B (1.00) AVPR1BAVPR1AOXTRAVPR2GPR65
Nelivaptan SCHEMBL14517029 1.00 AVPR1B (1.00) AVPR1BAVPR1AOXTRAVPR2GPR65
Nelivaptan SCHEMBL2798065 1.00 AVPR1B (1.00) AVPR1BAVPR1AOXTRAVPR2GPR65
Nelivaptan SCHEMBL29380118 1.00 AVPR1B (1.00) AVPR1BAVPR1AOXTRAVPR2GPR65
Nelivaptan SCHEMBL31317579 0.97 AVPR1B (0.95) AVPR1BAVPR1AOXTRAVPR2GPR65
SCHEMBL5351446 0.95 AVPR1B (0.91) AVPR1BAVPR1AOXTRAVPR2GPR65
SCHEMBL5347025 0.95 AVPR1B (0.90) AVPR1BAVPR1AOXTRAVPR2GPR65
SCHEMBL7403029 0.95 AVPR1B (0.90) AVPR1BAVPR1AOXTRAVPR2GPR65
SCHEMBL7408252 0.95 AVPR1B (0.90) AVPR1BAVPR1AOXTRAVPR2GPR65
SCHEMBL5351285 0.95 AVPR1B (0.90) AVPR1BAVPR1AOXTRAVPR2GPR65

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009140484-A1 PROCESSES FOR PREPARING AMORPHOUS DRUG SUBSTANCE SANOFI-AVENTIS (FR) 2009-11-19 WO claimed
WO-2009140479-A1 AMORPHOUS SOLID DISPERSIONS SANOFI-AVENTIS (FR) 2009-11-19 WO claimed
US-20210181182-A1 METHOD FOR IDENTIFICATION OF PERTURBAGENS OF PARTICULAR BIOLOGICAL PROCESSES AND CELL SYSTEMS WITHIN LIVING CELLS ATTAGENE INC (US) 2021-06-17 US disclosed
WO-2009140484-A1 PROCESSES FOR PREPARING AMORPHOUS DRUG SUBSTANCE SANOFI-AVENTIS (FR) 2009-11-19 WO disclosed
WO-2009140479-A1 AMORPHOUS SOLID DISPERSIONS SANOFI-AVENTIS (FR) 2009-11-19 WO disclosed
WO-2009140484-A1 PROCESSES FOR PREPARING AMORPHOUS DRUG SUBSTANCE SANOFI-AVENTIS (FR) 2009-11-19 WO disclosed
WO-2009140479-A1 AMORPHOUS SOLID DISPERSIONS SANOFI-AVENTIS (FR) 2009-11-19 WO disclosed
EP-1525198-A2 ACYLOXYPYRROLIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF Sanofi-Aventis (FR) 2005-04-27 EP disclosed
WO-2004009585-A2 ACYLOXYPYRROLIDINE DERIVATIVES AND USE THEREOF AS LIGANDS OF V1B OR BOTH V1B AND V1A RECEPTORS SANOFI-AVENTIS (FR) 2004-01-29 WO disclosed
EP-1255751-A2 1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES AND THEIR USE AS LIGANDS FOR V1B OR V1B AND V1A ARGININE-VASOPRESSIN RECEPTORS SANOFI-SYNTHELABO (FR) 2002-11-13 EP disclosed
WO-2001055130-A2 NOVEL 1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES AND THEIR USE AS LIGANDS FOR V1B AND V1A ARGININE-VASOPRESSIN RECEPTORS SANOFI-SYNTHELABO (FR) 2001-08-02 WO disclosed